抄録
Urinary hydroxyproline (HP) excretion was estimated, without prior dietary restriction in 70 patients (52 patients with prostatic cancer and 18 patients with benign prostatic hypertrophy) and expressed as either 24hr-HP output or as the hydroxyproline/creatinine (HP/Cr) ratio in a 24hr urine sample, an early morning urine sample, and spot urine sample.
Although each of the three different samplings had a wide daily variation in patients with active or controlled bone metastases, their HP and HP/Cr values were significantly higher than those in patients with localized prostatic cancer and benign prostatic hypertrophy. Among the three sampling types, 24hr-HP/Cr appears to be the most valuable for diagnosis.
The HP/Cr average over three days is useful in monitoring the response to treatment in patients with bony metastatic cancer. Among HP/Cr, Prostatic acid phosphatase and Alkaline phosphatase, HP/ Cr and Alkaline phosphatase are more sensitive markers of bony metastases.
